Replies to post #225023 on Biotech Values

[ghmm]

ADVM:

I thought the wording on the PR was a bit unusual a few other skeptics too:

https://twitter.com/MauriceOnTW/status/1129128336259715076

$ADVM Strange...."Given the encouraging robust anatomical response from patients in the first cohort, we will begin dosing patients in the second cohort at a lower dose of 2 x 10^11 vg/eye, instead of dose escalating as previously planned.”

— Miljenko Zuanic (@Miljenkoz) May 16, 2019

This has to be the most clever way to continue a clinical trial without escaping clinical hold, while disguising it as a release off of clinical hold, that I've ever seen...

— BiotechObserver (@BiotechObserver) May 16, 2019